BioLight Life Sciences Ltd. (IL:BOLT)
TASE:BOLT
Want to see IL:BOLT full AI Analyst Report?
Top Page
Biolight
(TASE:BOLT)
Select Model
Select Model
Rating:49Neutral
Price Target:
332.00
▼(-10.61% Downside)
Action:Reiterated
Date:06/16/26
Overall score is held back primarily by weak financial performance (zero/volatile revenue, persistent losses, and ongoing cash burn despite low leverage). Technicals are relatively supportive in the near-to-intermediate term, but valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Low leverage
Very low debt reduces refinancing and solvency risk, giving management structural flexibility to pursue R&D or partnerships without immediate pressure from lenders. Over a 2–6 month horizon this lowers bankruptcy risk and preserves options to raise capital on better terms.
Negative Factors
Revenue collapse
A drop to zero revenue signals failure to scale commercial sales and indicates the company remains pre‑commercial or losing customers. Over months this undermines prospects for self‑funding, weakens bargaining power with partners, and increases dependence on dilutive financing rounds.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low debt reduces refinancing and solvency risk, giving management structural flexibility to pursue R&D or partnerships without immediate pressure from lenders. Over a 2–6 month horizon this lowers bankruptcy risk and preserves options to raise capital on better terms.
Read all positive factors
Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪33.05M
Dividend YieldN/A
Average Volume (3M)11.86K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth-100.00%
EPS Growth-29.02%
CountryIL
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.98
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biolight Business Overview & Revenue Model
Company Description
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline incl...
How the Company Makes Money
null...
Biolight Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 219.00K | 118.00K | 63.00K | 3.00K |
| Gross Profit | -544.00K | 219.00K | 118.00K | 63.00K | 3.00K |
| EBITDA | -14.66M | -7.75M | -10.60M | -8.03M | -1.31M |
| Net Income | -11.73M | -7.14M | -26.02M | -7.85M | 382.00K |
Balance Sheet | |||||
| Total Assets | 42.41M | 34.12M | 33.45M | 57.01M | 64.17M |
| Cash, Cash Equivalents and Short-Term Investments | 23.65M | 13.47M | 8.64M | 17.63M | 33.71M |
| Total Debt | 772.00K | 599.00K | 91.00K | 527.00K | 443.00K |
| Total Liabilities | 2.24M | 3.38M | 3.15M | 3.32M | 2.75M |
| Stockholders Equity | 34.40M | 26.88M | 29.78M | 53.17M | 60.70M |
Cash Flow | |||||
| Free Cash Flow | -10.86M | -11.02M | -10.99M | -9.64M | -10.65M |
| Operating Cash Flow | -10.85M | -10.99M | -9.58M | -9.54M | -10.03M |
| Investing Cash Flow | -16.17M | 7.55M | -1.95M | -10.55M | 13.48M |
| Financing Cash Flow | 21.37M | 7.98M | 3.25M | -485.00K | 915.00K |
Biolight Technical Analysis
Positive
371.40
Price Trends
285.32
Positive
310.66
Positive
360.97
Positive
Market Momentum
17.27
Negative
63.69
Neutral
84.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Positive. The current price of 371.4 is above the 20-day moving average (MA) of 321.65, above the 50-day MA of 285.32, and above the 200-day MA of 360.97, indicating a bullish trend. The MACD of 17.27 indicates Negative momentum. The RSI at 63.69 is Neutral, neither overbought nor oversold. The STOCH value of 84.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:BOLT.
Biolight Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₪41.94M | -1.63 | ― | ― | -94.40% | 31.61% | |
49 Neutral | ₪33.05M | -2.56 | ― | ― | -100.00% | -29.02% | |
46 Neutral | ₪19.14M | -762.85 | ― | ― | ― | ― | |
43 Neutral | ₪32.42M | -0.24 | ― | ― | ― | -17.14% |
* Healthcare Sector Average
IL:BOLT
Biolight
364.00
-173.50
-32.28%
IL:XTLB
Xtl Bio
1.80
-2.10
-53.85%
IL:BLRX
Bioline Rx
1.60
-0.90
-36.00%
IL:CANF
Can Fite Bio
446.60
445.30
34253.85%
IL:PPBT
Purple Biotech
1.00
-3.30
-76.74%
IL:MTLF
Matricelf
274.80
36.80
15.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.